Fundraising Fox
/Companies
Sign in

Vivacelle Bio

Chicago, US · Founded 2013 · Delaware corporation · 17 employees on LinkedIn · 1 known investors

Find your way into Vivacelle Bio

Sign up to see every warm intro you have to Vivacelle Bio

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Vivacelle Bio team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Vivacelle Bio develops phospholipid nanoparticle therapies (VBI-S and VBI-1) that restore intravascular volume and redirect excess nitric oxide to treat hypovolemia in patients with septic shock or severe blood loss. The company is running a Phase III trial for its lead asset VBI-S in septic shock patients across U.S. sites.

BiotechHealthtechMedical Devices

Founders & leadership

Vivacelle Bio was founded in 2013 by Cuthbert Ormand Simpkins, Diane Simpkins, and Conrad Epting.

COCuthbert Ormand Simpkins
Cuthbert Ormand SimpkinsCo-founder
DSDiane Simpkins
Diane SimpkinsCo-founder · exec. admin.former
CEConrad Epting
Conrad EptingFounding Member / Scientific Consultant
HDHarven DeShield
Harven DeShieldChief Executive OfficerHarven DeShield holds a doctorate in biochemistry from the University of Buffalo and a J.D. from the University of Buffalo Law School with a concentration in intellectual property law; he is CEO of Vivacelle Bio and previously served as Chief Legal and Operations Officer there and VP of Commercialization and Business Development at a developmental-stage medical device company, with 18+ years of experience as a pharmaceutical and biomedical intellectual property attorney covering patent litigation, licensing, regulatory strategy, and corporate transactions.
PPaul
PaulCEO/CFO
SNStephen N. Keith
Stephen N. KeithFormer CEOStephen N. Keith is a physician and healthcare executive who served as CEO of Vivacelle Bio from 2015 to 2018 and has held senior roles in clinical research, pharmaceuticals, and healthcare consulting, including positions at Syneos Health, Panacea Pharmaceuticals, and Merck & Co. He is board-certified in pediatrics and a Fellow of the Academy of Pediatrics.

Board

RD
Ron DamperBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$4.2M disclosed across 2 rounds · 2014–2016

▶$2.9MraisedFeb 2019 · 59 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Cuthbert SimpkinsExecutive Officer, Director
  • Ron DamperDirector
  • Diane SimpkinsExecutive Officer, Director
  • Krishna TalluriExecutive Officer
  • Harven DeShieldExecutive Officer, Director
Offering amount
$3.4M
Amount sold
$2.9M
First sale
Aug 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedSep 2016 · 58 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ron DamperDirector
  • Harven DeShieldExecutive Officer, Director
  • Stephen KeithExecutive Officer, Director
  • Cuthbert Ormand SimpkinsExecutive Officer, Director
  • Diane SimpkinsExecutive Officer, Director
Offering amount
$1.3M
Amount sold
$1.3M
First sale
Jan 2014
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Vital Biosciences Inc.VitalBio develops the VitalOne, a diagnostic device that delivers comprehensive lab-grade blood test results in minutes from a small blood sample, using robotics, biochemistry, computer vision, and microfluidics. It targets healthcare providers and patients seeking point-of-care diagnostic testing.
Globus MedicalGlobus Medical designs and manufactures spine, trauma, and robotic surgical products for the orthopedic medical device market. The company serves hospitals and surgical centers globally.

Companies working in the same space as Vivacelle Bio.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2021$251.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients - BioSpacebiospace.com · Feb 2024Vivacelle Bio Integrates Sub-Saharan Africa Strategy into Series B Financing Roundprnewswire.com · Feb 2024

Frequently asked questions

What does Vivacelle Bio do?
Vivacelle Bio develops phospholipid nanoparticle therapies (VBI-S and VBI-1) that restore intravascular volume and redirect excess nitric oxide to treat hypovolemia in patients with septic shock or severe blood loss. The company is running a Phase III trial for its lead asset VBI-S in septic shock patients across U.S. sites.
Who founded Vivacelle Bio?
Vivacelle Bio was founded by Cuthbert Ormand Simpkins, Diane Simpkins, Conrad Epting in 2013.
Who are Vivacelle Bio's investors?
Vivacelle Bio's investors include 2Flo Ventures.
How much funding has Vivacelle Bio raised?
Vivacelle Bio has disclosed $4.2M raised across 2 rounds.
Where is Vivacelle Bio headquartered?
Vivacelle Bio is headquartered in Chicago, US.